David M. Goldenberg, MD, has been awarded the Society of Nuclear Medicine and Molecular Imaging's (SNMMI) Benedict Cassen Prize.
David M. Goldenberg, MD.SNMMI
The award is given every two years by the society's Education and Research Foundation for Nuclear Medicine and Molecular Imaging in recognition of outstanding work leading to a major advance in nuclear medicine science. During a special plenary session at SNMMI, Goldenberg presented the Cassen Lectureship, which was titled "My Golden Anniversary in Nuclear Medicine, 1974 to 2024."
Goldenberg is the founder and president of the Center for Molecular Medicine and Immunology (CMMI), funded by the U.S. National Cancer Institute. From 1983 to 2017, he was founder, chairman of the board, and chief scientist of Immunomedics. There, he was the inventor and principal developer of the antibody-drug conjugate sacituzumab govitecan (Trodelvy). It has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic, recurrent triple-negative breast cancer and metastatic, recurrent urothelial cancer, as well as HR+/HER2– metastatic breast cancer.
After receiving his medical degree from the University of Heidelberg in Germany and postgraduate training in Erlangen, Goldenberg served as a professor at five U.S. medical schools before founding the CMMI. He holds more than 400 scientific patents, has published more than 900 peer-reviewed articles, and has edited two books and 14 journal supplements. He has been on the editorial board of more than 25 medical journals, and his articles have been cited more than 60,000 times in the medical literature.
